Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

Piper Sandler analyst Kelsey Goodwin maintained a Buy rating on Relmada Therapeutics today and set a price target of $12.00. Goodwin covers the Hea...

Piper Sandler Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)

Relmada Therapeutics ( ($RLMD) ) has issued an announcement. On August 6, 2026, Relmada Therapeutics reported second-quarter 2026 results and detai...

Relmada Highlights Q2 Results and NDV-01 Pipeline Progress

The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). On July 28, 2026, Relmada Therapeutics appointed veteran biopharmaceutical ex...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$4.94	-8.01%	2.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$4.94	-8.0%	2.13M
3
4
5
6

RLMD

RLMD

Get Relmada Therapeutics, Inc. Data in Excel

Get Relmada Therapeutics, Inc. Data in Excel